BioNano Genomics Inc vs Palo Alto Networks Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Palo Alto Networks Inc trades at $356.79 (market cap $287.61B). The key difference: Palo Alto Networks Inc is far larger — about 21788.6× BioNano Genomics Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PANW | |
|---|---|---|
Market Cap | $13.20M | $287.61B |
Sector | Health | Technology |
52-Week High | $4.92 | $357.53 |
52-Week Low | $1.09 | $141.67 |
Enterprise Value | $15.81M | $286.57B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Palo Alto Networks (PANW) trades at $330.30, up 1.35% with a bullish technical outlook and strong earnings beats. The stock shows robust revenue growth to $9.22B in 2025 and a net income margin of 7.95%, though valuation ratios like P/E of 287.22 remain elevated. Recent news highlights cybersecurity sector tailwinds from AI-driven threats and IBM's client shifts, fueling positive sentiment.
Outlook is positive with 74% analyst buy ratings and a $336.65 consensus target, but high valuations and integration costs pose risks. Revenue growth and platformization strategy support upside, while competition and macroeconomic pressures require monitoring for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →